AstraZeneca and Eli Lilly said they will jointly develop a risky experimental Alzheimer's drug that could rake in as much as $5 billion in annual sales, but that AstraZeneca has said stands just a 9% chance of success.

NEXT
Topics:  eli lilly   alzheimer   astrazeneca   
BING NEWS:
  • Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
    With its 2-star rating, we believe Eli Lilly’s stock is overvalued compared ... and liability lawsuits. Lilly is developing a new Alzheimer’s drug, donanemab, that could become a major blockbuster, ...
    04/22/2024 - 12:59 pm | View Link
  • Eli Lilly buys injectable medicine manufacturing facility in Wisconsin
    Eli Lilly acquires manufacturing facility from Nexus Pharmaceuticals, expanding its global parenteral product manufacturing network to meet increased ...
    04/22/2024 - 3:36 am | View Link
  • Lilly, Roche to get expedited FDA review for blood test to diagnose Alzheimer’s disease
    The plasma biomarker test is designed to help physicians identify amyloid pathology, a key feature of Alzheimer’s disease. Roche and Lilly said they believe the test could play an important role in ...
    04/17/2024 - 3:41 am | View Link
  • More

 

NEXT
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

Movies With Butter More Movie News

More Business News